Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
Funded at Research Inst Nationwide Children's Hosp · NIH-11362251 · Data updated 2026-11-12
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,703,256 |
| NIH project number | 4R01CA291827-03 |
| Project ID | NIH-11362251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with somatostatin receptor 2 (SSTR2)–expressing neuroendocrine tumors who are candidates for radioligand therapy.
✕Less likely to help
Patients without SSTR2-expressing tumors or those for whom alpha-emitter therapy is contraindicated may not benefit.
What this research studies
Researchers are developing an alpha-emitter radioligand therapy that targets SSTR2 on neuroendocrine tumors and will study dosing strategies, biomarkers of kidney injury, and nephroprotective measures to minimize kidney damage while boosting tumor kill. They will use a theranostic pair to tailor treatment and non-invasive urine tests to monitor tubular injury. The work includes novel tumor models, dosimetry planning, and exploring how superoxide dismutase mimetics may limit nephrotoxicity. The study aims to define regimens that achieve strong tumor responses with reduced kidney risk in patients with NETs.
Why it matters
Potential benefit: If successful, patients with neuroendocrine tumors could receive more effective tumor control with fewer kidney-related side effects.
How similar studies have gone: Early clinical studies show high tumor responses with alpha-emitter approaches, and this project extends those gains while addressing nephrotoxicity.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
-
Receptor-targeted fluorescent guidance for pancreatic neuroendocrine tumor surgery
A new fluorescent dye that sticks to pancreatic neuroendocrine tumors is being developed to help surgeons see and remove tumors more clearly during surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.